FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)'s KT-621 for Eosinophilic Asthma [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
TheFly reported on April 13 that KYMR announced that the U.S. Food and Drug Administration granted Fast Track designation to KT-621, its first-in-class oral STAT6 degrader being developed for moderate to severe eosinophilic asthma. The investigational once-daily oral therapy is currently in ongoing Phase 2b clinical studies evaluating its potential in asthma and other Type 2 inflammatory conditions. Early clinical and preclinical data have shown reductions in key inflammatory biomarkers and improvements in disease control measures, supporting its mechanism of action. The designation is intended to facilitate closer regulatory engagement and may help accelerate development timelines for the program as it advances toward later-stage trials. FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)'s KT-621 for Eosinophilic Asthma Further reinforcing the company's operational momentum, on April 9, Gilead Sciences exercised its option under a collaboration agreement to
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026GlobeNewswire
- Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe AsthmaGlobeNewswire
- Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development CandidateGlobeNewswire
- Does Positive KT-621 Atopic Dermatitis Data Change The Bull Case For Kymera Therapeutics (KYMR)? [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]Yahoo! Finance
KYMR
Earnings
- 2/26/26 - Miss
KYMR
Sec Filings
- 4/24/26 - Form 4
- 4/24/26 - Form 4
- 4/22/26 - Form 144
- KYMR's page on the SEC website